6-K
File 001-15170
GSK PLC COMMENCES SHARE BUYBACK PROGRAMME
- Filing date
- 24 Feb 2025
- Reporting date
- 24 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,798 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 526-550 of 1,000 matching filings.
Per page
25
Current page
22
6-K
File 001-15170
DIRECTORATE CHANGE
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Feb 2025
- Reporting date
- 21 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NUCALA COPD SUBMISSION ACCEPTED IN CHINA
- Filing date
- 20 Feb 2025
- Reporting date
- 20 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA
- Filing date
- 18 Feb 2025
- Reporting date
- 18 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2025
- Reporting date
- 13 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Feb 2025
- Reporting date
- 11 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FINAL RESULTS
- Filing date
- 05 Feb 2025
- Reporting date
- 05 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 03 Feb 2025
- Reporting date
- 03 Feb 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN
- Filing date
- 28 Jan 2025
- Reporting date
- 28 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB
- Filing date
- 28 Jan 2025
- Reporting date
- 28 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION
- Filing date
- 27 Jan 2025
- Reporting date
- 27 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JEMPERLI EXPANDED APPROVAL IN THE EU
- Filing date
- 21 Jan 2025
- Reporting date
- 21 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 16 Jan 2025
- Reporting date
- 16 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 Jan 2025
- Reporting date
- 15 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 14 Jan 2025
- Reporting date
- 14 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Jan 2025
- Reporting date
- 13 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC.
- Filing date
- 13 Jan 2025
- Reporting date
- 13 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW
- Filing date
- 10 Jan 2025
- Reporting date
- 10 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION
- Filing date
- 07 Jan 2025
- Reporting date
- 07 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing